These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 8033373)

  • 1. Appearance of thyroid stimulating antibody and Graves' disease after radioiodine therapy for toxic nodular goitre.
    Chiovato L; Santini F; Vitti P; Bendinelli G; Pinchera A
    Clin Endocrinol (Oxf); 1994 Jun; 40(6):803-6. PubMed ID: 8033373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Appearance of anti TSH-receptor antibodies and clinical Graves' disease after radioiodine therapy for hyperfunctioning thyroid adenoma.
    Regalbuto C; Salamone S; Scollo C; Vigneri R; Pezzino V
    J Endocrinol Invest; 1999 Feb; 22(2):147-50. PubMed ID: 10195384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TSH-receptor autoantibodies - differentiation of hyperthyroidism between Graves' disease and toxic multinodular goitre.
    Wallaschofski H; Kuwert T; Lohmann T
    Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):171-4. PubMed ID: 15127319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assays of TSH-receptor antibodies in 576 patients with various thyroid disorders: their incidence, significance and clinical usefulness.
    Macchia E; Concetti R; Borgoni F; Cetani F; Fenzi GF; Pinchera A
    Autoimmunity; 1989; 3(2):103-12. PubMed ID: 2577491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appearance of Graves'-like disease after radioiodine therapy for toxic as well as non-toxic multinodular goitre.
    Nygaard B; Faber J; Veje A; Hegedüs L; Hansen JM
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):129-30. PubMed ID: 7641405
    [No Abstract]   [Full Text] [Related]  

  • 6. Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy.
    Nygaard B; Faber J; Veje A; Hegedüs L; Hansen JM
    Thyroid; 1999 May; 9(5):477-81. PubMed ID: 10365679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of stimulating thyrotropin receptor antibodies after radioiodine therapy for toxic multinodular goitre and Graves' disease measured with a novel bioassay.
    Hovens GC; Heemstra KA; Buiting AM; Stokkel MP; Karperien M; Ballieux BE; Pereira AM; Romijn JA; Smit JW
    Nucl Med Commun; 2007 Feb; 28(2):123-7. PubMed ID: 17198353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves' disease and multinodular toxic goitre: a comparison of two competitive binding assays.
    Pedersen IB; Knudsen N; Perrild H; Ovesen L; Laurberg P
    Clin Endocrinol (Oxf); 2001 Sep; 55(3):381-90. PubMed ID: 11589682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism.
    Franklyn JA; Daykin J; Holder R; Sheppard MC
    QJM; 1995 Mar; 88(3):175-80. PubMed ID: 7767667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of postradioiodine immunogenic hyperthyroidism/Graves' disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease.
    Schmidt M; Gorbauch E; Dietlein M; Faust M; Stützer H; Eschner W; Theissen P; Schicha H
    Thyroid; 2006 Mar; 16(3):281-8. PubMed ID: 16571091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thyrotropin receptor antibodies and Graves' disease, a side-effect of 131I treatment in patients with nontoxic goiter.
    Nygaard B; Knudsen JH; Hegedüs L; Scient AV; Hansen JE
    J Clin Endocrinol Metab; 1997 Sep; 82(9):2926-30. PubMed ID: 9284721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of thyroid function in Graves' patients treated with radioiodine: role of thyroid-stimulating and thyrotropin-blocking antibodies and of radioiodine-induced thyroid damage.
    Chiovato L; Fiore E; Vitti P; Rocchi R; Rago T; Dokic D; Latrofa F; Mammoli C; Lippi F; Ceccarelli C; Pinchera A
    J Clin Endocrinol Metab; 1998 Jan; 83(1):40-6. PubMed ID: 9435414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Development of Basedow disease after radioiodine therapy for nodular goiter].
    Cseke B; Balázs C
    Orv Hetil; 2003 Nov; 144(47):2327-9. PubMed ID: 14725052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in the properties of the thyrotropin receptor antibody in patients with Graves' disease after radioiodine treatment.
    Cho BY; Shong YK; Chung JK; Lee MC; Lee HK; Koh CS; Min HK
    Thyroidology; 1989 Dec; 1(3):109-14. PubMed ID: 2484872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
    Laurberg P; Wallin G; Tallstedt L; Abraham-Nordling M; Lundell G; Tørring O
    Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Appearance of Graves'-like disease following regression of autonomously functioning thyroid nodules. Two case reports.
    Orsolon P; Lupi A; De Antoni Migliorati G; Vianello Dri A
    Minerva Endocrinol; 1998 Jun; 23(2):53-6. PubMed ID: 9844355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term effects of radioiodine on thyrotrophin receptor antibodies in Graves' disease.
    Aizawa Y; Yoshida K; Kaise N; Kaise K; Fukazawa H; Kiso Y; Mori K; Sayama N; Kikuchi K; Abe K
    Clin Endocrinol (Oxf); 1995 May; 42(5):517-22. PubMed ID: 7621571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoimmune hyperthyroidism occurring late after radioiodine treatment for volume reduction of large multinodular goiters.
    Huysmans AK; Hermus RM; Edelbroek MA; Tjabbes T; Oostdijk ; Ross HA; Corstens FH; Kloppenborg PW
    Thyroid; 1997 Aug; 7(4):535-9. PubMed ID: 9292939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapses of hyperthyroidism in patients treated with radioiodine for nodular toxic goiter: relation to thyroid autoimmunity.
    Custro N; Ganci A; Scafidi V
    J Endocrinol Invest; 2003 Feb; 26(2):106-10. PubMed ID: 12739735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
    Berg GE; Michanek AM; Holmberg EC; Fink M
    J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.